{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:06:11Z","timestamp":1793297171362,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030679","name":"Mundipharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jinf.2025.106435","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:20:23Z","timestamp":1738754423000},"page":"106435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Rezafungin in special populations with candidaemia and\/or invasive candidiasis"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-3412","authenticated-orcid":false,"given":"Herv\u00e9","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-4602","authenticated-orcid":false,"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-6040","authenticated-orcid":false,"given":"Riina","family":"Rautemaa-Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0683","authenticated-orcid":false,"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5750","authenticated-orcid":false,"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2025.106435_bib1","unstructured":"World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action 2022. \u3008https:\/\/iris.who.int\/bitstream\/handle\/10665\/363682\/9789240060241-eng.pdf?sequence=1\u3009 [Accessed May 31, 2024]."},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myae046","article-title":"Informing the World Health Organization Fungal Priority Pathogens List (WHO-FPPL): a collection of systematic reviews","volume":"62","author":"Chen","year":"2024","journal-title":"Med Mycol"},{"key":"10.1016\/j.jinf.2025.106435_bib3","series-title":"Candidemia","author":"Mora Carpio","year":"2024"},{"issue":"7","key":"10.1016\/j.jinf.2025.106435_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dkad139","article-title":"Invasive candidiasis: current clinical challenges and unmet needs in adult populations","volume":"78","author":"Soriano","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","article-title":"Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study","volume":"23","author":"Hoenigl","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.jinf.2025.106435_bib6","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/jac\/dkx445","article-title":"What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead","volume":"73","author":"Bassetti","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 7","key":"10.1016\/j.jinf.2025.106435_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jinf.2025.106435_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2025.106435_bib9","unstructured":"ECMM. Candida One World \u2013 One Guideline; 2024. \u3008https:\/\/www.ecmm.info\/guidelines\/candidiasis\/\u3009 [Accessed 23 July, 2024]."},{"issue":"12","key":"10.1016\/j.jinf.2025.106435_bib10","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2025.106435_bib11","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2025.106435_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-024-00503-3","article-title":"Invasive candidiasis","volume":"10","author":"Lass-Fl\u00f6rl","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.jinf.2025.106435_bib13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jinf.2023.08.001","article-title":"European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: results from the ECMM Candida III study","volume":"87","author":"Arendrup","year":"2023","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib14","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","volume":"4","author":"Daneshnia","year":"2023","journal-title":"Lancet Microbe"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11046-023-00776-4","article-title":"Predictors for prolonged hospital stay solely to complete intravenous antifungal treatment in patients with candidemia: results from the ECMM Candida III multinational European observational cohort study","volume":"188","author":"Egger","year":"2023","journal-title":"Mycopathologia"},{"issue":"4","key":"10.1016\/j.jinf.2025.106435_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/jof9040468","article-title":"Prognostic trends and current challenges in candidemia: a comparative analysis of two multicenter cohorts within the past decade","volume":"9","author":"Agnelli","year":"2023","journal-title":"J Fungi"},{"issue":"1","key":"10.1016\/j.jinf.2025.106435_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/jof3010008","article-title":"Candida species biofilms' antifungal resistance","volume":"3","author":"Silva","year":"2017","journal-title":"J Fungi"},{"issue":"9","key":"10.1016\/j.jinf.2025.106435_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40266-018-0576-9","article-title":"Invasive candidiasis in the elderly: considerations for drug therapy","volume":"35","author":"Dekkers","year":"2018","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.jinf.2025.106435_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0000000000000931","article-title":"Therapeutic drug monitoring of the echinocandin antifungal agents: Is there a role in clinical practice? A position statement of the anti-infective drugs committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"44","author":"Kim","year":"2022","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1586\/14787210.2015.1028366","article-title":"Impact of special patient populations on the pharmacokinetics of echinocandins","volume":"13","author":"Muilwijk","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.jinf.2025.106435_bib21","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/jac\/dkx447","article-title":"Overview of antifungal dosing in invasive candidiasis","volume":"73","author":"Pea","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01339-23","article-title":"Absence of clinically meaningful drug-drug interactions with rezafungin: outcome of investigations","volume":"11","author":"Flanagan","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.diagmicrobio.2017.10.021","article-title":"Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris","volume":"90","author":"Berkow","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02603-17","article-title":"Population pharmacokinetic analyses for rezafungin (CD101) efficacy using Phase 1 data","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jinf.2025.106435_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jinf.2025.106435_bib26","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02614-17","article-title":"Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against Candida albicans and Candida glabrata","volume":"62","author":"Bader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jinf.2025.106435_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiot"},{"issue":"11","key":"10.1016\/j.jinf.2025.106435_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jinf.2025.106435_bib30","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jinf.2025.106435_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01626-16","article-title":"Pharmacokinetics of the novel echinocandin CD101 in multiple animal species","volume":"61","author":"Ong","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jinf.2025.106435_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jinf.2025.106435_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10370","key":"10.1016\/j.jinf.2025.106435_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised Phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2025.106435_bib36","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a Phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2025.106435_bib37","unstructured":"Melinta Therapeutics LLC. Rezzayo (rezafungin) US prescribing information; 2023. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf\u3009 [Accessed August 18, 2023]."},{"key":"10.1016\/j.jinf.2025.106435_bib38","unstructured":"Mundipharma GmbH. Rezzayo (rezafungin) summary of product characteristics; 2024. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rezzayo-epar-product-information_en.pdf\u3009 [Accessed May 14, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib39","unstructured":"Napp Pharmaceuticals Limited. Rezzayo (rezafungin acetate) UK public assessment report; 2024. \u3008https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/59081b042ab2804e873328b2a3ab82be265e9dcc\u3009 [Accessed May 15, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib40","unstructured":"Mundipharma. Mundipharma acquires all assets and rights related to REZZAYO\u00ae (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area; 2024. \u3008https:\/\/www.mundipharma.com\/mundipharma-acquires-all-assets-and-rights-related-to-rezzayo\u3009 [Accessed 12 Sep, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib41","unstructured":"Mundipharma Brasil Produtos M\u00e9dicos e Farmac\u00eauticos Ltda. Rezzayo (rezafungina) Bula do Profissional de Sa\u00fade [Health Professional Leaflet]; 2024. \u3008https:\/\/www.mundipharmapro.com\/pt-br\/sites\/mundipharmabr\/files\/2024-05\/Rezzayo_Bula_Profissional.pdf\u3009 [Accessed 12 Sep, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib42","first-page":"1199","article-title":"Treatment of invasive candidiasis in the elderly: a review","volume":"8","author":"Flevari","year":"2013","journal-title":"Clin Interv Aging"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2025.106435_bib44","first-page":"149","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jinf.2025.106435_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1044744","article-title":"Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA Adverse Event Reporting System database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jinf.2025.106435_bib46","unstructured":"Astellas Pharma Europe B.V. Mycamine (micafungin) summary of product characteristics; 2024. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mycamine-epar-product-information_en.pdf\u3009 [Accessed May 14, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib47","unstructured":"Pfizer Europe M.A.E.E.I.G. Ecalta (anidulafungin) summary of product characteristics; 2023. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ecalta-epar-product-information_en.pdf\u3009 [Accessed May 14, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib48","unstructured":"Pfizer Inc. Eraxis (anidulafungin) US prescribing information; 2020. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021632027_S029lbl.pdf\u3009 [Accessed May 10, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2147\/IDR.S165676","article-title":"Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation","volume":"11","author":"Yeoh","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jinf.2025.106435_bib50","unstructured":"Merck Sharp & Dohme B.V. Cancidas (caspofungin) US prescribing information; 2021. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206110s003lbl.pdf\u3009 [Accessed June 11, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib51","unstructured":"Merck Sharp & Dohme B.V. Cancidas (caspofungin) summary of product characteristics; 2023. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cancidas-epar-product-information_en.pdf\u3009 [Accessed May 14, 2024]."},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","article-title":"Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure","volume":"55","author":"Martial","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13318-014-0204-y","article-title":"Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction","volume":"40","author":"Undre","year":"2015","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.jinf.2025.106435_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00063-18","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jinf.2025.106435_bib56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ajhp\/zxad021","article-title":"Echinocandin exposures in obese patients: a scoping review and clinical perspectives","volume":"80","author":"Alsowaida","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jinf.2025.106435_bib57","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","article-title":"Drug disposition in obesity: toward evidence-based dosing","volume":"55","author":"Knibbe","year":"2015","journal-title":"Annu Rev Pharm Toxicol"},{"issue":"7","key":"10.1016\/j.jinf.2025.106435_bib58","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1473-3099(06)70523-0","article-title":"Obesity and infection","volume":"6","author":"Falagas","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2025.106435_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-023-01332-5","article-title":"Patients with obesity should be recognised as a special patient population during drug development of antibacterial and antifungal agents; a call to action","volume":"63","author":"van Rhee","year":"2024","journal-title":"Clin Pharm"},{"issue":"4","key":"10.1016\/j.jinf.2025.106435_bib60","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jac\/dky554","article-title":"Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults","volume":"74","author":"Wasmann","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2025.106435_bib61","unstructured":"Astellas Pharma Europe B.V. Mycamine (micafungin) US prescribing information; 2021. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212125s000lbl.pdf\u3009 [Accessed June 11, 2024]."},{"issue":"1","key":"10.1016\/j.jinf.2025.106435_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01390-21","article-title":"Metabolism, excretion, and mass balance of [(14)C]-rezafungin in animals and humans","volume":"66","author":"Ong","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/phar.2943","article-title":"Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate\/severe hepatic impairment and matched control subjects","volume":"44","author":"Flanagan","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jinf.2025.106435_bib64","unstructured":"Flanagan S., Lakota E.A., Rubino C.M., Sandison T., Pappas P.G., Ostrosky-Zeichner L. Phase 2 STRIVE clinical trial of rezafungin for the treatment of candidemia and\/or invasive candidiasis: results stratified by baseline renal function. ECCMID. April 13\u201316, 2019; Amsterdam, Netherlands."},{"issue":"12","key":"10.1016\/j.jinf.2025.106435_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00916-23","article-title":"Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis","volume":"67","author":"Roepcke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jinf.2025.106435_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00842-21","article-title":"Population pharmacokinetics of rezafungin in patients with fungal infections","volume":"65","author":"Rubino","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2025.106435_bib67","unstructured":"Flanagan S., Honore P.M., Soriano A., Vazquez J., Sandison T. Efficacy and safety by renal function in the Phase 2 STRIVE trial of rezafungin in treatment of candidemia and invasive candidiasis (IC). ICHS. January 31 to February 2, 2021; Melbourne, Australia."},{"key":"10.1016\/j.jinf.2025.106435_bib68","doi-asserted-by":"crossref","unstructured":"Sandison T., Vazquez J., Honore P.M., Sandison T., Horcajada J.P., Slavin M. Rezafungin treatment of candidemia and invasive candidiasis: outcomes stratified by baseline renal function \u2013 analysis of the Phase 2 + Phase 3 trials. ICHS. February 17\u201319, 2022; Virtual.","DOI":"10.1093\/jacamr\/dlad066.031"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib69","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000489212","article-title":"Ex vivo rezafungin adsorption and clearance during continuous renal replacement therapy","volume":"46","author":"Jang","year":"2018","journal-title":"Blood Purif"},{"key":"10.1016\/j.jinf.2025.106435_bib70","doi-asserted-by":"crossref","unstructured":"Vazquez J., Flanagan S., Pappas P.G., Thompson G.R., Sandison T., Honore P.M. Outcomes by body mass index (BMI) in the STRIVE Phase 2 trial of once-weekly rezafungin for treatment of candidemia and invasive candidiasis compared with caspofungin. IDWeek. October 21\u201325, 2020; Virtual.","DOI":"10.1093\/ofid\/ofaa439.831"},{"key":"10.1016\/j.jinf.2025.106435_bib71","doi-asserted-by":"crossref","unstructured":"Cornely O.A., Thompson G.R.I., Soriano A., Kullberg B.J., Kollef M., Vazquez J., et al. Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and\/or invasive candidiasis: integrated analysis of pooled Phase 2 and Phase 3 data. ECCMID. April 15\u201318, 2023; Copenhagen, Denmark.","DOI":"10.1093\/jacamr\/dlad143.033"},{"key":"10.1016\/j.jinf.2025.106435_bib72","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib73","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/380637","article-title":"Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000","volume":"38","author":"Marchetti","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2025.106435_bib74","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","article-title":"Invasive candidiasis in critical care: challenges and future directions","volume":"46","author":"Logan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jinf.2025.106435_bib75","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13054-024-05152-2","article-title":"Length of hospital and intensive care unit stay in patients with invasive candidiasis and\/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials","volume":"28","author":"Honore","year":"2024","journal-title":"Crit Care"},{"key":"10.1016\/j.jinf.2025.106435_bib76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13054-024-05117-5","article-title":"Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: analysis of the ReSTORE and STRIVE randomised trials","volume":"28","author":"Honore","year":"2024","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.jinf.2025.106435_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad079","article-title":"Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis","volume":"5","author":"Jeck","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jinf.2025.106435_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01750-17","article-title":"CD101, a novel echinocandin, possesses potent antibiofilm activity against early and mature Candida albicans biofilms","volume":"62","author":"Chandra","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib79","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.46.6.1773-1780.2002","article-title":"Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins","volume":"46","author":"Kuhn","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2025.106435_bib80","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1128\/AAC.00211-08","article-title":"In vitro activity of anidulafungin against Candida albicans biofilms","volume":"52","author":"Jacobson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jinf.2025.106435_bib81","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1128\/AAC.46.11.3591-3596.2002","article-title":"In vitro activity of caspofungin against Candida albicans biofilms","volume":"46","author":"Bachmann","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jinf.2025.106435_bib82","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ja.2013.83","article-title":"In vitro effectiveness of anidulafungin against Candida sp. biofilms","volume":"66","author":"Rosato","year":"2013","journal-title":"J Antibiot"},{"key":"10.1016\/j.jinf.2025.106435_bib83","unstructured":"European Commission. Rezafungin acetate product information; 2023. \u3008https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/o2385.htm\u3009 [Accessed January 3, 2024]."},{"key":"10.1016\/j.jinf.2025.106435_bib84","doi-asserted-by":"crossref","unstructured":"Sandison T., Ramos-Martinez A., Kim Y.K., Chai L.Y., Slavin M. Rezafungin efficacy and safety in immunocompromised patients: subanalyses of the Phase 3 trial in the treatment of candidemia and invasive candidiasis. ICHS. February 17\u201319, 2022; Virtual.","DOI":"10.1093\/jacamr\/dlad066.032"},{"issue":"5","key":"10.1016\/j.jinf.2025.106435_bib85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/myc.12748","article-title":"Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia","volume":"61","author":"Chandrasekar","year":"2018","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.jinf.2025.106435_bib86","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/jac\/dkx116","article-title":"Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials","volume":"72","author":"Kullberg","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:43:06Z","timestamp":1759300986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0163445325000295"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106435","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rezafungin in special populations with candidaemia and\/or invasive candidiasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106435"}}